SERVE-HF: Substudy on the Mechanistic Plausibility of the Clinical Benefits of Adaptive Servo-ventilation
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Heart Failure
- Sponsor
- ResMed
- Enrollment
- 312
- Locations
- 94
- Primary Endpoint
- Change in Left Ventricular Ejection Fraction (LVEF) from baseline to 12 months of therapy as measured by echocardiography (Echo).
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
The purpose of this study is to assess changes in left ventricular performance using echocardiography as well as ventricular remodelling, changes in sleep and changes in mood, anxiety and cognitive functions occurring as a result of treatment of predominant central sleep apnoea by adaptive servoventilation (ASV) in chronic heart failure in addition to optimal medical therapy in chronic heart failure. This will be a substudy of the SERVE-HF study.
Detailed Description
This substudy is performed within the SERVE-HF Study, a randomised, multi-centre,international trial with parallel group design, with patients randomised to either control (optimal medical management) or active treatment (optimal medical treatment plus use of adaptive servoventilation) in a 1:1 ratio. The randomization will be the same as in the parent study. For this purpose, the randomization of the parent study will be stratified as to whether a patient is included in the substudy or not. 300 patients will be recruited for the substudy overall. For the purpose of this substudy, patients will be followed up for a period of 12 months. The following extra tests will be performed at the baseline visit, the 3 months follow up and the 12 months follow up: * Echocardiogram (for both groups) * cMRI (for both groups) * PSG (at the baseline visit only for patients in the treatment group and at 3 months follow up and the 12 months follow up for all patients) * 4 questionnaires (for both groups) * Additional blood testing (for both groups)
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Change in Left Ventricular Ejection Fraction (LVEF) from baseline to 12 months of therapy as measured by echocardiography (Echo).
Time Frame: Baseline (Randomization), 6- and 12 month-Follow-up-visit
Secondary Outcomes
- Changes in sleep-disordered breathing(Baseline (Randomization), 6- and 12-month-Follow-up-visit)
- Changes in left and right ventricular function(Baseline (Randomization), 6-and 12-month-Follow-up visit)
- Changes in LV systolic and diastolic indexed volumes(Baseline (Randomization), 6- and 12-month-Follow-up-visit)
- Changes in right ventricular (RV) systolic and diastolic indexed volumes(Baseline (Randomization), 6- and 12-month-Follow-up-visit)
- Changes in LV and RV mass(Baseline (Randomization), 6- and 12-month-Follow-up-visit)
- Changes in LV sphericity index and LV end-systolic global wall stress(Baseline (Randomization), 6- and 12-month-Follow-up-visit)
- Changes in sleep duration and sleep stages as well as arousals(Baseline (Randomization), 6- and 12-month-Follow-up-visit)
- Changes in quality of life assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ)(Baseline (Randomization), 6- and 12-month-Follow-up-visit)
- Changes in mental status assessed by Mini-Mental State Examination (MMSE)(Baseline (Randomization), 6- and 12-month-Follow-up-visit)
- Changes in Patient Health Questionnaire-9 (PHQ-9) score and Patient Anxiety Questionnaire GAD-7(Baseline (Randomization), 6- and 12-month-Follow-up-visit)